Jairo Cajamarca-Baron1, Diana Guavita-Navarro2, Jhon Buitrago-Bohorquez2, Laura Gallego-Cardona2, Angela Navas3, Hector Cubides4, Ana María Arredondo4, Alejandro Escobar4, Adriana Rojas-Villarraga5. 1. Fundación Universitaria de Ciencias de la Salud (FUCS), Hospital San José, Bogotá, Colombia. Electronic address: jairocajamarca@hotmail.com. 2. Fundación Universitaria de Ciencias de la Salud (FUCS), Hospital San José, Bogotá, Colombia. 3. Servicio de Neurología, Fundación Universitaria de Ciencias de la Salud (FUCS), Hospital San José, Bogotá, Colombia. 4. Servicio de Reumatología, Hospital San José, Bogotá, Colombia. 5. Servicio de Reumatología, Instituto de Investigaciones, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Abstract
BACKGROUND: It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people. OBJECTIVE: To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies. RESULTS: Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis (MS), neuromyelitis optica (NMODS), myasthenia gravis (MG)), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes. CONCLUSION: Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
BACKGROUND: It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people. OBJECTIVE: To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies. RESULTS:Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis (MS), neuromyelitis optica (NMODS), myasthenia gravis (MG)), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes. CONCLUSION: Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
Keywords:
Cancer; Coronavirus; Cáncer; Diseases of the nervous system; Enfermedades del sistema nervioso; Enfermedades reumáticas; Human immunodeficiency virus; Immunosuppression; Inmunosupresión; Rheumatic diseases; Transplantation; Trasplante; Virus de la inmunodeficiencia humana
Authors: Eustache Paramithiotis; Scott Sugden; Eszter Papp; Marie Bonhomme; Todd Chermak; Stephanie Y Crawford; Stefanie Z Demetriades; Gerson Galdos; Bruce L Lambert; John Mattison; Thomas McDade; Stephane Pillet; Robert Murphy Journal: Front Immunol Date: 2022-05-26 Impact factor: 8.786
Authors: Lexin Zhou; Nekane Romero-García; Juan Martínez-Miranda; J Alberto Conejero; Juan M García-Gómez; Carlos Sáez Journal: JMIR Public Health Surveill Date: 2022-03-30
Authors: Helena Enocsson; Cornelia Idoff; Annette Gustafsson; Melissa Govender; Francis Hopkins; Marie Larsson; Åsa Nilsdotter-Augustinsson; Johanna Sjöwall Journal: Front Med (Lausanne) Date: 2021-12-02